The Technical Analyst
Sema4 Holdings Corp. [SMFR]
Exchange: NASDAQ Global Select Sector: Healthcare Industry: Medical - Healthcare Information Services
Sema4 Holdings Corp. Price, Forecast, Insider, Ratings, Fundamentals & Signals
26.78% $0.311
/ 10 jan 2023 @ 00:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 246.37 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | N/A |
| SharesOutstanding: | 793.21 mill |
| Avg Daily Volume: | 2.01 mill |
| RATING 2023-03-10 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 0.248 - 0.374 ( +/- 20.28%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-19 | Saad Kareem | Buy | 546 | Class A Common Stock |
| 2024-01-22 | Saad Kareem | Sell | 193 | Class A Common Stock |
| 2024-01-19 | Saad Kareem | Sell | 546 | Restricted Stock Unit |
| 2024-01-11 | Ryan Jason | Sell | 73 614 | Class A Common Stock |
| 2024-01-03 | Saad Kareem | Sell | 105 | Class A Common Stock |
| INSIDER POWER |
|---|
| 2.85 |
| Last 100 transactions |
| Buy: 1 476 375 | Sell: 1 378 748 |
Forecast:
01:40 - $0.259
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.311 (26.78% ) |
| Volume | 4.71 mill |
| Avg. Vol. | 2.01 mill |
| % of Avg. Vol | 234.22 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SMFR
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
SMFR
Sema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.
Latest News
2024-01-29 15:01:04 - PYMNTS
Sema4.ai Secures $30.5 Million to Bring AI to Enterprise Work
Artificial intelligence (AI) company Sema4.ai has secured $30.5 million in funding to bring open source-powered AI to enterprise work. The company aims to redefine the future of knowledge work by developing intelligent agents that transform how knowledge workers collaborate with AI, Sema4.ai said in a Monday (Jan. 29) press release.
2022-12-22 22:29:04 - Seeking Alpha
Sema4: Restructuring Plan Figures Don't Add Up
Sema4's restructuring plan has a number of potential downsides that could affect the company's cash position in the coming few quarters. The booting of the CEO signals the start of a strategic focus on short-term survival away from long-term growth.
2022-11-14 22:46:04 - Seeking Alpha
Sema4 Holdings Corporation (SMFR) Q3 2022 Earnings Call Transcript
Sema4 Holdings Corporation (NASDAQ:SMFR ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Joel Kaufman - VP, Finance & Corporate Development Katherine Stueland - CEO & Director Kevin Feeley - SVP, Operations & CFO Conference Call Participants Mark Massaro - BTIG David Delahunt - Goldman Sachs Operator Welcome to the Sema4 Third Quarter 2022 Earnings Conference Call. My name is Cheryl, and I will be your operator for today's call.
2022-08-16 11:32:46 - The Motley Fool
Why Sema4 Holdings Stock Is Crashing Today
2022-08-15 21:29:11 - Seeking Alpha
Sema4 Holdings Corp (SMFR) CEO Katherine Stueland on Q2 2022 Results - Earnings Call Transcript
Sema4 Holdings Corp (NASDAQ:SMFR ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Joel Kaufman - VP, Finance & Corporate Development Katherine Stueland - CEO & Director Kevin Feeley - SVP, Operations and Head of GeneDx Conference Call Participants David Delahunt - Goldman Sachs Group Matt Kim - Jeffrey Max Masucci - Cowen and Company Mark Massaro - BTIG Operator Good day, and thank you for standing by. Welcome to the Sema4 Second Quarter 2022 Earnings Conference Call.
2022-07-18 12:02:12 - Seeking Alpha
Sema4 Holdings, Big Data For Precision Medicine Solutions
Big data and machine learning are booming also in healthcare, where it enables precision medicine and population health platform services. Sema4 Holdings has amassed huge amounts of medical data and a sophisticated platform in order to extract valuable insight from these for health systems, pharma companies and individuals.
2022-06-21 13:27:11 - Zacks Investment Research
Sema4 Holdings Corp. (SMFR) Moves to Buy: Rationale Behind the Upgrade
Sema4 Holdings Corp. (SMFR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2022-05-12 22:52:07 - Seeking Alpha
Sema4 Holdings Corp. (SMFR) CEO Katherine Stueland on Q1 2022 Results - Earnings Call Transcript
Sema4 Holdings Corp. (NASDAQ:SMFR ) Q1 2022 Earnings Conference Call May 13, 2022 4:30 PM ET Company Representatives Katherine Stueland - Chief Executive Officer Eric Schadt - Founder, President and Chief R&D Officer Isaac Ro - Chief Financial Officer Joel Kaufman - Vice President of Finance and Corporate Development Conference Call Participants Mark Massaro - BTIG Max Masucci - Cowen and Company Dave Delahunt - Goldman Sachs Operator Good day! And thank you for standing by.
2022-03-14 19:57:07 - Seeking Alpha
Sema4 Holdings Corp. (SMFR) CEO Eric Schadt on Q4 2021 Results - Earnings Call Transcript
Sema4 Holdings Corp. (SMFR) CEO Eric Schadt on Q4 2021 Results - Earnings Call Transcript
2022-01-18 09:39:29 - Benzinga
Sema4 Strengthens AI-Driven Genomic, Clinical Data Platform With $623M GeneDx Acquisition
Sema4 Holdings Corp (NASDAQ: SMFR) has agreed to acquire OPKO Health Inc's (NASDAQ: OPK) wholly-owned subsidiary, GeneDx Inc, for approximately $623 million. Sema4 will acquire GeneDx for an upfront payment of $150 million in cash plus 80 million shares in Sema4, with up to an additional $150 million revenue-based milestones over the next two years.